Glutathione biosynthetic pathway (GSH pathway) (GSH pathway)

The glutathione biosynthetic pathway is a fundamental metabolic process responsible for the production of glutathione (GSH), a tripeptide that serves as the primary endogenous antioxidant in mammalian cells (PubChem). The pathway consists of two sequential ATP-dependent reactions: the ligation of glutamate and cysteine by glutamate-cysteine ligase (GCL), followed by the addition of glycine by glutathione synthetase (GSS) (UniProt). GSH is essential for maintaining cellular redox homeostasis, detoxifying reactive oxygen species (ROS), and facilitating the conjugation of xenobiotics for excretion (PubMed). In clinical practice, the pathway is targeted to either replenish GSH levels, as seen with N-acetylcysteine (NAC) treatment for acetaminophen toxicity, or to deplete GSH to induce ferroptosis in cancer cells using inhibitors like buthionine sulfoximine (BSO) (StatPearls, Nature Reviews Cancer). Dysregulation of this pathway is implicated in various pathologies, including neurodegenerative diseases, chronic liver conditions, and cancer progression. Consequently, modulating glutathione production remains a key strategy for both cytoprotection and targeted oncological therapies.

Other names

Glutathione synthesisGSH productionGamma-glutamyl cycleGlutathione metabolism

The pathway is targeted through the inhibition of rate-limiting enzymes like glutamate-cysteine ligase (GCL) to deplete glutathione levels, or through the provision of rate-limiting precursors like N-acetylcysteine to boost antioxidant capacity.